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Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease
Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin
Sunil Parikh,1* Jun Liu,2 Puran Sijwali,1 Jiri Gut,1 Daniel E. Goldberg,2 and Philip J. Rosenthal1
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Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease
inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine
protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than
against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and
against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mecha-
nism of HIVPIs differs from that of pepstatin.
Human immunodeficiency virus type 1 (HIV-1) and malaria
are coendemic throughout much of the developing world.
HIV-1 expresses an aspartic protease, which is an important
drug target (3). In addition to their important antiretroviral
activity, HIV-1 protease inhibitors (HIVPIs) are active against
Plasmodium falciparum in vitro and against rodent malaria
parasites in murine models (7, 9, 13). The predicted targets of
these inhibitors are plasmepsins, a family of aspartic proteases
of malaria parasites. A number of plasmepsins act in concert
with falcipain cysteine proteases and other enzymes to hydro-
lyze hemoglobin in the P. falciparum food vacuole (5, 8). Sev-
eral HIVPIs inhibit the food vacuole protease plasmepsin II
(7) and a homologous protease of the rodent parasite Plasmo-
dium chabaudi (6). Pepstatin, the most-studied aspartic pro-
tease inhibitor, also exhibits activity against cultured malaria
parasites and inhibits several plasmepsins (2, 6). As the anti-
malarial activity of HIVPIs may have important implications in
areas where those treated for HIV-1 infection are at risk of
malaria, and as both HIVPIs and pepstatin may serve as leads
for new antimalarial agents, it was of interest to compare their
antimalarial mechanisms of action.
Insight into the antimalarial mechanisms of protease in-
hibitors came from studies that showed that cysteine pro-
tease inhibitors [N-(trans-epoxysuccinyl)-L-leucine-4-guanidino-
butylamide (E-64)] and aspartic protease inhibitors (pepstatin)
display marked synergy against malaria parasites (1, 10). Further
supporting an important interaction between these two classes of
proteases, pepstatin had markedly enhanced activity against P.
falciparum parasites in which the gene for the cysteine protease
falcipain-2 was disrupted (11). It was of interest to determine
if HIVPIs had effects similar to those of pepstatin.
We evaluated the HIVPI lopinavir for synergy with E-64. P.
falciparum (W2 strain) parasites were cultured in RPMI me-
dium supplemented with 10% serum and synchronized with
5% D-sorbitol as previously described (11). Ring stage para-
sites were incubated with study drugs (0.039 to 10 M, from
stock solutions concentrated 1,000-fold in dimethyl sulfoxide
[DMSO]) or with equivalent concentrations of DMSO for 48 h,
fixed with 1% formaldehyde in phosphate-buffered saline for
48 h, and labeled with 1 nM YOYO-1 dye (Molecular Probes) in
0.1% Triton X-100 in phosphate-buffered saline. Parasitemias
were determined from dot plots acquired with a FACSort flow
cytometer, and 50% inhibitory concentration (IC50) values were
calculated as previously described (11, 12). Potential synergy was
evaluated as the sum of the fractional inhibitory concentrations
(sum FIC) by the following equation: sum FIC  [(IC50 drug
A in combination)/(IC50 drug A alone)]  [(IC50 drug B in
combination)/(IC50 drug B alone)]. The sum FIC value for
lopinavir and E-64 was 2.04  0.48 (mean  standard devia-
tion of results from two experiments, each done in triplicate).
Thus, lopinavir and E-64 (Sigma-Aldrich) showed no evidence
of synergism, but rather borderline antagonism. In contrast,
E-64 and pepstatin have shown marked synergy with a sum FIC
value of 0.54  0.16 (10).
To further characterize the antimalarial mechanism of
HIVPIs, we tested the compounds against P. falciparum para-
sites with disrupted food vacuole proteases. For plasmepsin
knockout parasites, previously described 3D7 strain parasites
were used (5). For falcipain-2 knockout parasites, procedures
very similar to those previously described were used (11).
Briefly, 3D7 strain parasites were transfected with the pHTK-
FP2 plasmid, selected with WR99210 until integration of the
plasmids was detected, enriched for recombinant parasites
through negative selection with ganciclovir, and cloned to ob-
tain pure recombinant parasites. Wild-type 3D7 and plasmep-
sin knockout parasites were incubated in microwell cultures in
the presence of serial dilutions of lopinavir, ritonavir, and
saquinavir (0.025 to 150 M, from 1,000-fold-concentrated
* Corresponding author. Mailing address: University of California
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stocks in DMSO) or with equivalent concentrations of DMSO
for 44 h, beginning at the ring stage, and then 0.5 Ci of
[3H]hypoxanthine (178.7 Ci/mmol; Perkin Elmer) was added.
The incubation was continued for 16 h, the parasites were
harvested, the hypoxanthine uptake rates of treated and con-
trol parasites were compared, and IC50 values were generated
as previously described (5). The antimalarial activities of seven
HIVPIs against 3D7 wild-type and falcipain-2 knockout para-
sites were evaluated by assessing the fluorescence of YOYO-
1-stained parasites and determining IC50 values using fluores-
cence-activated cell sorter-based analysis as described above
(11, 12).
HIVPIs had similar activities against control, plasmepsin
knockout (Table 1), and falcipain-2 knockout (Table 2) para-
sites. Discrepancies between reported IC50 values in Tables 1
and 2 likely reflect differences between the [3H]hypoxanthine
uptake and fluorescence-activated cell sorter-based assay
methods. Considering the actions of other protease inhibitors,
E-64 was about twice as active against falcipain-2 knockout and
plasmepsin knockout parasites as it was against control para-
sites, as previously described (5). Pepstatin (Sigma-Aldrich)
was about equally active against control and plasmepsin knock-
out parasites but was much more active against falcipain-2
knockout parasites, all consistent with prior findings (5, 11).
Our results identify major differences between the antima-
larial activities of pepstatin and HIVPIs. Pepstatin, the most
widely available broadly active aspartic protease inhibitor (3),
inhibits multiple plasmepsins and rapidly kills cultured para-
sites, but its antimalarial mechanism of action is uncertain. For
both pepstatin and HIVPIs, activities were similar against wild-
type and plasmepsin knockout parasites. These results suggest
the functional redundancy of plasmepsins but do not shed light
on the mechanism of HIVPIs. In contrast, the activities of
pepstatin and HIVPIs differed markedly when evaluated for
antimalarial synergy with the cysteine protease inhibitor E-64
or for activity against falcipain-2 knockout parasites. Pepstatin
shows strong synergy with cysteine protease inhibitors (10),
and it is remarkably more potent against falcipain-2 knockout
parasites than against wild-type parasites (11). These results
suggest important biological interactions between falcipains
and plasmepsins. Surprisingly, the HIVPIs were not synergistic
with E-64 and were not more active against falcipain-2 knock-
out parasites than against wild-type parasites. Thus, although
we cannot yet identify specific biological targets for either
pepstatin or HIVPIs in malaria parasites, our results strongly
suggest that the compounds act differently.
P. falciparum encodes 10 predicted aspartic protease genes
(14). In addition to the four food vacuole plasmepsins (I to
IV), another quite different aspartic protease, plasmepsin V,
was recently characterized (4). This protease is not located in
the food vacuole and does not bind pepstatin. The HIV-1
protease is also quite different from the food vacuole plas-
mepsins (15). These structural differences may offer insight
into the differential effects of the HIVPIs and pepstatin. Pre-
viously we showed that HIVPIs inhibit recombinant plasmep-
sin II (7), but the intracellular target of these inhibitors is
unknown. Thus, pepstatin may target food vacuole plas-
mepsins, which are dependent on food vacuole cysteine pro-
teases for maximal activity, while HIVPIs may target other
aspartic proteases, such as plasmepsin V. In addition to differ-
ential inhibition of parasite proteases, various effects may be
due to differential access to the food vacuole or other cellular
compartments. Alternatively, either pepstatin or HIVPIs might
exert antimalarial effects that are unrelated to protease inhi-
bition. Our results do not yet identify a specific mechanism of
action for HIVPIs, but they offer the surprising finding that
HIVPIs do not, as would have been predicted, act in the same
manner as pepstatin. Further research into the precise mode of
action of HIVPIs and other antimalarial aspartic protease in-
hibitors is warranted to provide insight into the development of
protease inhibitors as new antimalarial drugs and to under-
stand the means by which antiretroviral drugs may offer pro-
tection against malaria.
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